enGene Holdings Inc. (ENGN)
(Real Time Quote from BATS)
$14.70 USD
-0.23 (-1.54%)
Updated May 8, 2024 03:47 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENGN 14.70 -0.23(-1.54%)
Will ENGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ENGN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ENGN
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
enGene initiated with bullish view at Wells Fargo, here's why
enGene initiated with bullish view at Guggenheim
/C O R R E C T I O N -- enGene Inc./
Buy Rating Justified by EG-70’s Potential in NMIBC Treatment and Strategic Commercial Prospects